Ceftetrame and cefetamet (Ro 15-8074), two new orally administered aminothiazolyl imimomethoxy cephalosporins, inhibited hemolytic streptococci and Streptococcus pneumoniae at .0.5 ,ug/ml but were less active against staphylococci than were cephalexin and cefaclor. They did not inhibit S. faecalis, S. faecium, Listeria monocytogenes, Corynebacterium JK species, or Pseudomonas aeruginosa. Haemophilus influenzae, Branhamella catarrhalis, and Neisseria gonorrhoeae, including ampicillin-resistant isolates, were inhibited at <0.25 ,ug/ml. Both agents inhibited Escherichia coli, Klebsiella pneumoniae, K. oxytoca, Proteus mirabilis, Salmonella species, Shigella species, Citrobacter diversus, and Aeromonas hydrophila resistant to ampicillin, cephalexin, and cefaclor at .2 ,ug/ml, although many isolates of Enterobacter cloacae, Citrobacter freundii, and Serratia marcescens resistant to cefotaxime were not inhibited by these agents. A marked inoculum effect was noted for Enterobacteriaceae carrying the Richmond-Sykes type 1A chromosomally mediated beta-lactamases, but plasmid-mediated beta-lactamases did not hydrolyze the compounds. Both drugs inhibited the chromosomally mediated beta-lactamase of E. cloacae, P99. Although there has been great progress in the development of parenteral cephalosporins stable to attack by betalactamases and active against a wide spectrum of grampositive and -negative bacteria, this goal has not been achieved for oral cephalosporins (2). The early oral cephalosporins, cephalexin and cephradine, although moderately stable to attack by beta-lactamases, have had relatively poor activity against important respiratory pathogens such as Haemophilus influenzae and Br-anhacmellai catarrhalis (1, 7). Furthermore, their activity against Streptococcus pneiumoniae is significantly lower than that of the parenteral cephalosporins, and these compounds do not inhibit many beta-